strong semi-dur hcv lower po
remain buy
anoth strong mavyret qtr partial off-set humira
report stronger anticip result revenu non-gaap ep
beat estim respect mainli driven anoth stronger
expect quarter mavyret hepat hcv base updat
modestli increas sale driven mavyret outlook modestli
reduc forecast base conserv us humira
outlook reduc po blend dcf price-to-earnings
due modestli lower compani sale mainli humira lower gross
margin mainli due product mix higher discount rate discount abbvi
cash flow prior line pharma peer group reiter buy
rate strong mavyret launch encourag new product cycl four clinic
derisk launch attract dividend yield vs us major peer
takeaway call
focu result us humira perform compani lower
sale guidanc cite de-stock conserv gross-
to-net assumpt base expect util compani co-pay assist
program updat us humira sale guidanc call y/i growth management
indic includ mid-singl digit net price benefit look ahead still earli
payer contract process us humira would expect major chang
magnitud discount/reb paid us humira mavyret deliv blow-out
quarter outpac forecast management rais product sale guidanc
ask durabl hcv market management indic
market go around long long time big market
forecast mavyret sale declin base clif
compound-annual-growth-rate upadacitinib rheumatoid arthriti follow fda adcom
vote approv competitor lli baricitinib high dose management
emphas clinic program design assess risk-benefit dose
independ expect provid thromboembol event rate sometim
final registr studi complet come month
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
research-bas global pharmaceut
busi spun abbott
develop market drug area
immunolog virolog oncolog
buy thesi base street
underappreci strength humira
formul patent combin patent
litig timelin give us confid
see us biosimilar
optimist commerci potenti
next-gener immunolog agent
signific negoti leverag biosimilar
develop think like lead
patent settlement push biosimilar
launch
price object po base blend valuat risk-adjust dcf
target price-to-earnings multipl non-gaap ep estim base ep growth
profil assum wacc termin growth rate believ dcf
assumpt reason minim contribut pipelin
valid late-stag clinic studi histor trade discount
peer price-to-earnings owe humira biosimilar risk multipl expand
last month believ warrant base humira settlement
pipelin readout risk earlier-than-anticip launch humira biosimilar
us clinic pipelin failur
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
